北 京 同 仁 堂 國 藥 有 限 公 司 （ 於 香 港 註 冊 成 立 之 有 限 公 司 ） （ 股 份 代 號 ： 3613） 持續關連交易 有關續訂北京同仁堂集團中國分銷框架協議 續訂北京同仁堂集團中國分銷框架協議 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而 產生或因依賴該等內容而引致的任何損失承擔任何責任。 BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED 茲提述本公司日期為 2023 年 2 月 20 日之公告，內容有關（其中包括）本公司與同仁堂集 團公司所訂立之現有北京同仁堂集團中國分銷框架協議項下進行之持續關連交易。 由於現有北京同仁堂集團中國分銷框架協議將於 2025 年 12 月 31 日屆滿，於 2025 年 12 月 30 日，本公司與同仁堂集團公司訂立續訂北京同仁堂集團中國分銷框架協議，以進一步重 續截至 2028 年 12 月 31 日止為期約三年的中國分銷安排。 上市規則的涵義 於本公告日期，同仁堂集團公司於 ...

香 港 交 易 及 結 算 所 有 限 公 司 及 香 港 聯 合 交 易 所 有 限 公 司 對 本 公 告 的 內 容 概 不 負 責 ， 對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明 ， 並 明 確 表 示 概 不 就 因 本 公 告 全 部 或 任 何 部 分 內 容 而 產 生 或 因 依 賴 該 等 內 容 而 引 致 的 任 何 損 失 承 擔 任 何 責 任 。 BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED 北 京 同 仁 堂 國 藥 有 限 公 司 （於香港註冊成立之有限公司） （股份代號： 3613） 持 續 關 連 交 易 有 關 續 訂 租 賃 框 架 協 議 續 訂 租賃框架協議 茲提述 本公司 日 期 為 2022 年 12 月 30日 的公告，內容有關 與同仁堂集團公司 所 訂 立 現 有 租 賃 框 架 協 議 項 下 的 持 續 關 連 交 易 。 由 於 現 有 租 賃 框 架 協 議 將 於 2025 年 12 月 31日 屆 滿 ， 本 公 司 與 同 仁 堂 集 團 公 司 於 20 ...

Core Insights - Tencent Holdings (00700), Alibaba-W (09988), and Hong Kong Exchanges (00388) led the market in net inflows, with amounts of 1.115 billion, 1.055 billion, and 309 million respectively [1] - China Mobile (00941), Luoyang Molybdenum (03993), and CICC (03908) experienced the highest net outflows, with amounts of -1.053 billion, -184 million, and -181 million respectively [1] - In terms of net inflow ratios, China Telecom Services (00552), Yihua Tong (02402), and Sunshine Insurance (06963) topped the list with ratios of 167.31%, 126.18%, and 118.17% respectively [1] Net Inflow Rankings - Tencent Holdings (00700) had a net inflow of 1.115 billion, representing a 13.09% increase, closing at 614.500 [2] - Alibaba-W (09988) saw a net inflow of 1.055 billion, with a 12.23% increase, closing at 146.400 [2] - Hong Kong Exchanges (00388) recorded a net inflow of 309 million, with a 24.77% increase, closing at 407.000 [2] Net Outflow Rankings - China Mobile (00941) faced a net outflow of -1.053 billion, a decrease of -54.21%, closing at 83.700 [2] - Luoyang Molybdenum (03993) had a net outflow of -184 million, down by -29.82%, closing at 19.100 [2] - CICC (03908) experienced a net outflow of -181 million, a decrease of -30.22%, closing at 20.540 [2] Net Inflow Ratio Rankings - China Telecom Services (00552) achieved a net inflow ratio of 167.31%, with a net inflow of 26.5926 million, closing at 4.520 [3] - Yihua Tong (02402) had a net inflow ratio of 126.18%, with a net inflow of 26.5481 million, closing at 23.980 [3] - Sunshine Insurance (06963) recorded a net inflow ratio of 118.17%, with a net inflow of 31.5558 million, closing at 3.940 [3]

Core Viewpoint - The article highlights the innovative integration of traditional Chinese medicine (TCM) with cultural, commercial, and tourism sectors by Beijing Tongrentang Group, emphasizing its strategic importance for future development and consumer engagement [1][4][6]. Group 1: Integration of TCM and Cultural Tourism - Beijing Tongrentang is transforming traditional consumer experiences by creating new retail environments that blend health products, dining, and cultural experiences, moving away from the conventional pharmacy model [4][5]. - The company is leveraging its cultural heritage and TCM as a lifestyle practice to foster sustainable and experiential consumer engagement [4][5]. - Initiatives such as the establishment of "Tongrentang Day" and participation in major sports events illustrate the company's commitment to cultural integration and consumer interaction [4][5]. Group 2: Collaborative Practices and Resource Integration - Tongrentang has formed partnerships with various brands to create unique offerings, such as herbal hot pot and commemorative products, enhancing its market presence [5][6]. - The company has developed a collaborative mechanism involving 15 entities to facilitate resource sharing and cross-industry cooperation, evolving from initial market events to broader applications in hotels and tourist areas [5][6]. - Recent collaborations with high-end hotels and tourist attractions aim to incorporate TCM wellness services into luxury travel experiences, showcasing the brand's adaptability [5][6]. Group 3: Innovation and Quality Development - The "14th Five-Year Plan" period has seen Tongrentang focus on high-quality development through technological innovation, sustainable practices, and international expansion [8][9]. - The company has established a robust R&D framework, resulting in over 800 domestic patents and the launch of nearly 300 new products since the beginning of the 14th Five-Year Plan [8][9]. - Smart manufacturing initiatives have been implemented, including the development of intelligent factories and digital production lines, enhancing operational efficiency and product quality [9][10]. Group 4: Market Expansion and Global Outreach - Tongrentang has registered over 1,200 product varieties for export and has established a significant international presence, providing services to over 30 million people globally [11]. - The company views its international outlets as cultural ambassadors, promoting TCM through various initiatives, including cultural experience centers and health ambassador programs [11]. - The establishment of cultural display areas and health seminars abroad reflects Tongrentang's commitment to globalizing its brand and TCM practices [11]. Group 5: Future Directions and Strategic Planning - As the company approaches the end of the 14th Five-Year Plan, it is focusing on technological innovation and digital transformation as key components of its future strategy [12][14]. - The upcoming "15th Five-Year Plan" emphasizes enhancing core competencies, fostering research reforms, and ensuring comprehensive collaboration across its business units [14][15]. - Talent development is prioritized, with plans for systematic training and recruitment of high-quality professionals to support innovation and organizational growth [15][17].

Core Viewpoint - The Hong Kong government has officially released the "Traditional Chinese Medicine Development Blueprint," which aims to promote comprehensive, high-quality, and high-level development of traditional Chinese medicine (TCM) in Hong Kong [1][2] Group 1: Development Goals - The blueprint includes eight goals, such as optimizing clinical services, establishing a cross-professional service system, and leading the development of TCM professionals [1][2] - Goals also focus on enhancing the quality of Chinese medicine, establishing international standards, driving research and innovation, promoting TCM culture, and facilitating the global outreach of TCM services [2] Group 2: Industry Outlook - CITIC Securities indicates that the short-term pressure on the Chinese medicine industry is expected to ease, with channel inventory clearing accelerating and demand expected to recover by year-end [1][3] - Huajin Securities emphasizes the importance of the "premium + innovation" strategy in the Chinese medicine sector, highlighting the strong brand effect and pricing power of premium Chinese medicine products [3] Group 3: Company Highlights - China Traditional Chinese Medicine (00570) reported a revenue of approximately 7.46 billion RMB for the first half of 2025, a year-on-year decrease of 11.0%, with a gross profit of about 3.63 billion RMB, down 10.5% [5] - Tong Ren Tang (03613) is a historic brand in the Chinese medicine industry, producing over 400 types of traditional Chinese medicine products [6] - Guo Sheng Tang (02273) is actively expanding its presence in Singapore through a strategy of mergers, partnerships, and self-built initiatives [6] - Baiyunshan (00874) reported a revenue of 61.606 billion RMB for the first three quarters of 2025, an increase of 4.31% year-on-year, with a net profit of 3.31 billion RMB, up 4.78% [6]

Core Viewpoint - The Hong Kong government has officially released the "Traditional Chinese Medicine Development Blueprint," aiming to promote comprehensive, high-quality, and high-level development of traditional Chinese medicine (TCM) in Hong Kong, encompassing five areas, eight goals, and twenty actions [1][2]. Group 1: Development Goals - The eight goals include optimizing clinical services, establishing a cross-professional service system, leading the development of TCM professions, enhancing the quality of TCM, building international standards for TCM, driving research and innovation in the industry, promoting TCM culture, and facilitating the global outreach of TCM [1][2]. - The government aims to enhance the quality of TCM services and integrate them into the healthcare system, thereby improving public health and establishing Hong Kong as a bridge for TCM to the world [2][3]. Group 2: Industry Outlook - CITIC Securities indicates that the short-term pressure on the TCM industry is expected to ease, with channel inventory clearing accelerating, and anticipates a demand rebound by year-end, along with opportunities for fundamental and valuation improvements [1][3]. - Huajin Securities emphasizes the importance of the "premium + innovation" strategy in the TCM sector, highlighting that premium TCM products possess significant medical value and consumer attributes, while innovative TCM is gradually entering a harvest period supported by favorable policies [3][4]. Group 3: Company Highlights - China Traditional Chinese Medicine (00570) reported a revenue of approximately 7.46 billion RMB for the first half of 2025, a year-on-year decrease of 11.0%, with a gross profit of about 3.63 billion RMB, down 10.5%, but with a gross margin of 48.7%, up 0.3 percentage points from the previous year [5]. - Tong Ren Tang (03613), a historic brand in the TCM industry, produces over 400 types of traditional Chinese medicine, covering various medical fields [5][6]. - Guo Sheng Tang (02273) is actively expanding its TCM services in Singapore through a strategy of mergers, partnerships, and self-built initiatives, including a recent joint venture with a digital healthcare platform [6]. - Baiyunshan (00874) reported a revenue of 61.606 billion RMB for the first three quarters of 2025, an increase of 4.31% year-on-year, with a net profit of 3.31 billion RMB, up 4.78% [6].

Core Viewpoint - A product labeled as "Beijing Tongrentang 99% High Purity Antarctic Krill Oil" has been found to contain no actual krill oil, raising serious concerns about consumer rights and product authenticity [1][2]. Group 1: Product Details and Issues - The product in question is "Antarctic Krill Oil Gel Candy," with a purchase price of 3-3.7 yuan per 60g bottle, while the retail price ranges from 40-60 yuan per bottle, indicating a significant markup [2]. - The Shanghai Consumer Protection Committee revealed that the product was produced using fish oil extract instead of the claimed Antarctic krill oil, misleading consumers regarding its core benefits [2][3]. - The manufacturer, Anhui Habao Pharmaceutical Co., admitted that the claimed Antarctic krill oil was not added during production, while the distributor, Beijing Tongrentang (Sichuan) Health Pharmaceutical Co., avoided responsibility during discussions [1][2]. Group 2: Company Responses and Actions - Beijing Tongrentang Health Pharmaceutical Co. issued a statement on December 15, 2025, ordering the cessation of sales of the implicated product and initiating a full investigation [2][3]. - The company also announced plans to pursue legal action against the involved parties for unauthorized use of the "Beijing Tongrentang" name on the product packaging [2][6]. - The Shanghai Consumer Protection Committee urged the distributor to conduct a self-examination, apologize to consumers, and recall the problematic products for refunds and compensation [3][4]. Group 3: Regulatory and Ethical Concerns - The Shanghai Consumer Protection Committee raised questions about who is the mastermind behind the misleading practices, highlighting discrepancies between the statements of Anhui Habao Pharmaceutical and Beijing Tongrentang (Sichuan) [4][5]. - Concerns were expressed regarding the integrity of the operators involved, questioning their social responsibility in selling a product that misrepresents its contents and harms consumer rights [7]. - The committee emphasized the need for stronger regulations to protect consumers and ensure the healthy development of the functional food industry [7].

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京同仁堂國藥有限公司 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 不適用 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 03613 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 837,100,000 | | 0 | | 837,100,000 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 837,100,000 | | 0 | | 837,100,000 | ...

Core Viewpoint - Tong Ren Tang Guo Yao (03613.HK) announced the termination of the existing trademark licensing agreement with Tong Ren Tang Group, which was established on April 15, 2013, and will end on December 31, 2025. A new trademark licensing framework agreement has been signed on November 28, 2025, allowing the company to use the "Tong Ren Tang" name and certain trademarks from January 1, 2026, to December 31, 2027 [1] Group 1 - The existing trademark licensing agreement allows the company to use the Tong Ren Tang Group's trademarks without any fees [1] - The new trademark licensing framework agreement extends the use of the "Tong Ren Tang" name and certain trademarks for an additional two years [1] - The agreement transition indicates a continued partnership between the company and Tong Ren Tang Group [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告 全部或任何部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責 任 。 BEIJING TONG REN TANG CHINESE MEDICINE COMPANY LIMITED 北 京 同 仁 堂 國 藥 有 限 公 司 （於香港註冊成立之有限公司） （股份代號： 3613） 持 續 關 連 交 易 有 關 新 商 標 許 可 框 架 協 議 新商標 許可框架 協 議 茲提述 本公司於 2013年 4月 25日 的 招股章程 ， 內 容 有 關 （ 其 中 包 括 ） 與 同 仁 堂集團公司 於 2013年 4月 15日 訂 立 現 有 商標許可協議 ， 據 此 ，本公司 無 須 就 使 用 同 仁 堂 集 團 公 司 商 標 繳 付 任 何 費 用 或 收 費 。 經 訂 約 方 一 致 同 意 ， 現 有 商 標 許 可 協 議 將 於 2025年 12月 31日 終 止 。 本 公 司 與 同 仁 堂 集 團 公 司 於 2025年 11月 28日 （ 交 易 ...